PDS Biotechnology (PDSB) Non-Current Assets (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Non-Current Assets came in at $2.2 million in Q4 2025, up 636.32% YoY from $304214.0 in Q4 2024, and down 67.12% on a QoQ basis from $6.8 million in Q3 2025.
PDS Biotechnology (PDSB) Non-Current Assets (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Non-Current Assets data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Non-Current Assets rose 636.32% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.4 million (up 1498.65% YoY) and the FY2025 annual result came in at $2.2 million, up 636.32% from the prior year.
- Non-Current Assets eased to $2.2 million in Q4 2025, from $6.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q2 2025 to a low of $258188.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $405254.5 in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 2843.48% — and 2022, when it sank 43.42%.
- Tracing PDSB's Non-Current Assets over 5 years: stood at $357697.0 in 2021, then jumped by 47.48% to $527533.0 in 2022, then sank by 36.5% to $335005.0 in 2023, then declined by 9.19% to $304214.0 in 2024, then soared by 636.32% to $2.2 million in 2025.
- The last three Non-Current Assets figures came in at $2.2 million (Q4 2025), $6.8 million (Q3 2025), and $6.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 6.81 Mn |
| Jun 30, 2025 | 6.83 Mn |
| Mar 31, 2025 | 4.56 Mn |
| Dec 31, 2024 | 304,214.00 |
| Sep 30, 2024 | 319,342.00 |
| Jun 30, 2024 | 334,471.00 |
| Mar 31, 2024 | 320,601.00 |
| Dec 31, 2023 | 335,005.00 |
| Sep 30, 2023 | 349,409.00 |
| Jun 30, 2023 | 403,301.00 |
| Mar 31, 2023 | 475,259.00 |
| Dec 31, 2022 | 527,533.00 |
| Sep 30, 2022 | 475,416.00 |
| Jun 30, 2022 | 258,188.00 |
| Mar 31, 2022 | 308,327.00 |
| Dec 31, 2021 | 357,697.00 |
| Sep 30, 2021 | 407,208.00 |
| Jun 30, 2021 | 456,336.00 |